Eli Lilly and Company

Thomas John Bleisch

Paul Leslie Ornstein

Dennis Michael Zimmerman

Hamideh Zarrinmayeh

Macklin Brian Arnold

Ana Maria Escribano

Edward C R Smith

Richard L Simon

Stephen Richard Baker

Buddy Eugene Cantrell

Bryan Hurst Norman

Thomas M Wilson

Sandra Ann Filla

Jose Eduardo Lopez

Ken Matsumoto

Tracey E McKennon

Jose Antonio Martinez-Perez

David R Helton

Winton Dennis Jones, Jr

Darryle D Schoepp

Zhaogen Chen

Kuo-Long Yu

Andrew Michael Ratz

Freddie Craig Stevens

Joseph P Tizzano

Lance Allen Pfeifer

Mary Jeanne Kallman

Esteban Dominguez-Manzanares

David Michael Bender

Douglas Linn Gernert

Ana Isabel Mateo Herranz

Robert Eugene Stratford, Jr

David Bleakman

Scott Alan Jones

Ana Maria Castano Mansanet

Robert Anthony Doti

Christian Alexander Clarke

M Brian Arnold

Scott Allan May

Theodore Curtis Jessop

Edward Louis Mattiuz

Jeffrey Alan Dodge

Charles Willis Iii Lugar

The present invention provides a compound of Formula I: wherein R is or a pharmaceutically acceptable salt thereof, useful for treating psoriasis, systemic lupus erythematosus, or type 1 diabetes.

Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of interferon signaling

The present invention provides compounds of the formula (I) or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors useful in the treatment of pain associated with osteoarthritis. 

Dihydropyrido pyrimidine compounds as autotaxin inhibitors

The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).

Excitatory amino acid receptor antagonists

The present invention relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.

Sulphonamide derivatives

The present invention provides novel compounds of Formula (I), or the pharmaceutically acceptable salts or prodrugs thereof, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.

The present invention provides compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising compounds or Formula I or Formula II, and methods for treating neurological disorders and neurodegenerative diseases, particularly migraine.

The present invention provides certain amide, carbamate and urea derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.

Amide, carbamate, and urea derivatives

The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.

Sulfonamide derivatives

The present invention relates to novel prodrug forms of 3S,4aR,6S,8aR-6-(((4-carboxy)phenyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid, to pharmaceutical compositions containing the prodrug forms, and to methods of using the prodrug forms.

Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid

The present invention provides compounds of formula ##STR1## in which R represents an organic group, or a pharmaceutically acceptable metabolically labile ester or amide thereof, or a pharmaceutically acceptable salt thereof, which are useful as antagonists of one or more of the actions of L-glutamate at metabotropic excitatory amino acid receptors.

Growing community of inventors

Noblesville, IN, United States of America

Thomas John Bleisch